Werewolf Therapeutics Inc’s recent filing unveils that its 10% Owner MPM BioVentures 2014, L.P. unloaded Company’s shares for reported $2061.0 on Mar 27 ’25. In the deal valued at $1.05 per share,1,963 shares were sold. As a result of this transaction, MPM BioVentures 2014, L.P. now holds 3,208,793 shares worth roughly $3.27 million.
Then, EVNIN LUKE sold 2,425 shares, generating $2,546 in total proceeds. Upon selling the shares at $1.05, the Director now owns 4,309,860 shares.
Before that, GADICKE ANSBERT sold 4,386 shares. Werewolf Therapeutics Inc shares valued at $4,605 were divested by the 10% Owner at a price of $1.05 per share. As a result of the transaction, GADICKE ANSBERT now holds 6,718,670 shares, worth roughly $6.85 million.
JMP Securities initiated its Werewolf Therapeutics Inc [HOWL] rating to a Mkt outperform in a research note published on April 03, 2024; the price target was $12. A number of analysts have revised their coverage, including Wedbush’s analysts, who began to cover the stock in late August with a ‘”an Outperform”‘ rating. BofA Securities started covering the stock on September 10, 2021. It rated HOWL as “a Buy”.
Price Performance Review of HOWL
On Tuesday, Werewolf Therapeutics Inc [NASDAQ:HOWL] saw its stock jump 2.00% to $1.02. Over the last five days, the stock has gained 9.68%. Werewolf Therapeutics Inc shares have fallen nearly -31.08% since the year began. Nevertheless, the stocks have fallen -81.69% over the past one year. While a 52-week high of $5.73 was reached on 01/03/25, a 52-week low of $0.60 was recorded on 04/07/25. SMA at 50 days reached $0.9639, while 200 days put it at $1.6685.
Levels Of Support And Resistance For HOWL Stock
The 24-hour chart illustrates a support level at 0.9507, which if violated will result in even more drops to 0.8813. On the upside, there is a resistance level at 1.0797. A further resistance level may holdings at 1.1393. The Relative Strength Index (RSI) on the 14-day chart is 58.02, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 0.0371, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bullish at 18.50%. Stochastics %K at 71.43% indicates the stock is a holding.
The most recent change occurred on May 25, 2021 when SVB Leerink began covering the stock and recommended ‘”an Outperform”‘ rating along with a $29 price target.
